Sato, Mototaka <br/><br/>
EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome.  [electronic resource] 

 -  PloS one  2013 
 - e74313 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0074313  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Animals<br/>Apoptosis<br/>Basigin--physiology<br/>Blotting, Western<br/>Carcinoma, Renal Cell--blood supply<br/>Cell Movement<br/>Cell Proliferation<br/>Down-Regulation<br/>Drug Resistance, Neoplasm<br/>Female<br/>Humans<br/>Immunoenzyme Techniques<br/>Indoles--pharmacology<br/>Kidney--drug effects<br/>Kidney Neoplasms--blood supply<br/>Male<br/>Mice<br/>Mice, Inbred BALB C<br/>Middle Aged<br/>Neoplasm Invasiveness<br/>Neoplasm Staging<br/>Neovascularization, Pathologic--metabolism<br/>Pyrroles--pharmacology<br/>RNA, Messenger--genetics<br/>RNA, Small Interfering--genetics<br/>Real-Time Polymerase Chain Reaction<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Sunitinib<br/>Tumor Cells, Cultured